Illumina, Inc.

US$213.13As of Sun 8 Nov 2026, 12:00 UTC

NASDAQ:ILMNHealthcare

Country USA

PE (Fwd) •••

TSR 10Y CAGR 4.87%

Div yield —

ROE 32.39%

Diagnostics & Research

Beta (5Y) 1.45

PE TTM 36.58

TSR TTM 72.52%

Mkt cap US$32.23B

ROIC 17.59%

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$229

7.51%

121.36%

Hold 8|6|2|2|4

TTM

FYE 31 Dec USD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

2.812

Revenue$B

7.400

7.971

8.321

8.933

9.605

10.07

10.76

11.13

11.56

12.29

3.012

5.06%

5.99%

20.13

Revenue growth%

0.40

1.31

0.52

0.40

0.90

3.43

3.34

5.36

2.81

4.33

25.23

3.43

2.06

23.47

Gross margin%

19.86

16.88

16.59

14.61

16.83

18.49

17.87

15.07

13.75

15.05

4.30

15.07

16.71

26.71

Operating margin%

31.07

30.03

28.99

30.90

32.49

32.40

32.52

34.42

31.92

34.91

16.21

32.52

32.16

3.61

Net margin%

14.29

16.25

16.09

19.01

19.04

20.72

21.38

21.56

22.86

22.31

28.24

21.56

19.88

13.65

P/E ratio (avg)x

11.81

12.97

14.43

14.73

17.17

16.98

19.52

21.34

25.52

26.28

23.85

21.34

17.07

33.58

EV/EBITx

20.53

20.43

22.54

23.34

24.47

27.87

27.25

30.37

28.75

32.46

23.00

28.75

25.86

17.53

FCF yield (avg)%

22.21

24.90

26.14

28.25

30.24

28.81

27.94

26.10

25.29

25.76

4.42

26.10

26.12

5.17

FCF margin%

9.49

10.57

9.29

8.08

8.31

8.65

10.99

8.99

6.96

7.26

18.30

8.65

8.82

0.544

FCF / Net incomex

2.044

2.335

2.294

2.498

2.807

2.866

3.100

3.294

3.864

1.336

3.294

2.837

16.20

ROIC%

4.79

7.35

5.11

5.28

3.52

5.65

3.14

1.00

0.40

0.65

20.08

1.00

4.16

15.83

Return on equity%

24.02

22.44

20.75

18.19

20.69

23.00

25.08

24.35

22.01

20.50

25.74

23.00

22.22

17.11

Return on assets%

18.22

20.87

23.85

23.55

21.74

24.60

24.84

24.80

24.42

25.08

26.58

24.80

24.13

8.06

EPS$

6.05

6.06

6.37

6.10

6.40

6.16

5.82

6.07

6.06

6.80

9.00

1.24%

1.97%

—

27.31

EPS growth%

10.70

11.77

9.57

8.37

5.76

7.11

6.99

4.27

4.97

6.65

18.47

6.65

7.05

20.85

Bookvalue per sh$

10.45

8.88

8.92

7.97

8.66

8.34

7.32

6.97

6.29

6.26

5.33

(6.27%)

(6.53%)

—

7.63

FCF per share$

27.47

31.60

30.88

29.22

27.25

30.08

33.19

35.40

33.84

31.23

17.95

2.77%

1.77%

—

11.36

Dividend per sh$

11.65

10.87

10.57

11.50

12.39

11.32

10.36

9.04

8.77

9.60

9.76

(4.97%)

(2.38%)

—

8.76

Div yield (avg)%

18.98

21.68

21.05

19.02

18.96

20.17

18.83

19.54

19.50

22.30

29.44

19.54

19.52

19.21

Payout ratio%

6.83

7.90

6.54

9.01

10.02

12.49

10.23

8.80

6.86

7.92

21.43

8.80

8.36

150.1

Shares (diluted)M

187.8

200.6

225.3

220.2

219.0

251.2

289.4

295.2

321.3

376.3

150.8

11.43%

8.51%

28.78

Buyback yield%

20.27

21.07

19.04

17.46

15.76

18.30

17.52

16.39

18.12

19.24

9.48

18.12

18.21

1.239

D/E ratiox

1.951

1.929

1.953

2.209

2.136

2.062

2.233

2.634

2.689

2.875

1.368

2.634

2.172

9.601

Enterprise value$B

10.65

9.937

10.77

10.40

10.79

9.374

8.147

9.015

8.992

8.331

5.583

(5.03%)

(1.77%)

6.556

LT debt$B

11.89

12.74

12.09

11.15

10.99

11.69

13.35

13.70

12.97

14.40

4.515

5.55%

2.87%

Peers (US$32.23B)

Cap (US$)

IQVIA Holdings Inc.

44.80B

32.93x

Labcorp Holdings Inc.

29.77B

30.10x

Quest Diagnostics…

28.12B

25.47x

Mettler-Toledo…

34.25B

37.31x

Capital

TTM

10Y

Leveragex

1.270

0.756

0.628

EBIT/Intx

1.171

0.240

0.219

Own earn%

130.94

(47.84)

(40.90)

Sh yield%

37.54

37.62

38.05

Owners

Insiders/Inst%

10.46

39.87

Short interest%

0.68

SBC / revenue%

1.23

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

29–35

$1 testx

—

Incr. ROIC%

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$12.29B

5.99%

1.00×

Cost of revenue

$7.214B

6.14%

1.01×

Operating expenses

$2.501B

6.07%

1.01×